Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.

Biotech R&D: A Decade of Strategic Investment

__timestampHalozyme Therapeutics, Inc.Intra-Cellular Therapies, Inc.
Wednesday, January 1, 20147969600021226345
Thursday, January 1, 20159323600087718074
Friday, January 1, 201615084200093831530
Sunday, January 1, 201715064300079419009
Monday, January 1, 2018150252000132166913
Tuesday, January 1, 201914080400089124838
Wednesday, January 1, 20203423600065782137
Friday, January 1, 20213567200088845513
Saturday, January 1, 202266607000134715000
Sunday, January 1, 202376363000180142000
Monday, January 1, 202479048000
Loading chart...

Data in motion

A Decade of Innovation: R&D Trends in Biotech Giants

In the ever-evolving world of biotechnology, research and development (R&D) is the lifeblood of innovation. Over the past decade, Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc. have been at the forefront of this transformative journey. From 2014 to 2023, these companies have shown remarkable dedication to advancing medical science, with R&D expenses reflecting their commitment.

Intra-Cellular Therapies, Inc. has seen a staggering 750% increase in R&D spending, peaking in 2023. This surge underscores their relentless pursuit of groundbreaking therapies. Meanwhile, Halozyme Therapeutics, Inc. experienced a more modest 4% growth, with notable fluctuations, particularly in 2016 and 2017, when their R&D expenses reached their zenith.

These trends highlight the dynamic nature of biotech investments, where strategic R&D allocation can be the key to unlocking future medical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025